Aligos Therapeutics, Inc. (ALGS)
5.34
+0.03
(+0.56%)
USD |
NASDAQ |
Oct 09, 16:00
5.32
-0.02
(-0.37%)
After-Hours: 20:00
Aligos Therapeutics Enterprise Value : 6.386M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 6.386M |
| October 08, 2026 | 6.198M |
| October 07, 2026 | 6.261M |
| October 06, 2026 | 6.635M |
| October 05, 2026 | 6.760M |
| October 02, 2026 | 7.633M |
| October 01, 2026 | 7.383M |
| September 30, 2026 | 8.194M |
| September 29, 2026 | 8.132M |
| September 28, 2026 | 7.633M |
| September 25, 2026 | 7.446M |
| September 24, 2026 | 7.695M |
| September 23, 2026 | 7.758M |
| September 22, 2026 | 8.506M |
| September 21, 2026 | 7.321M |
| September 18, 2026 | 5.762M |
| September 17, 2026 | 5.325M |
| September 16, 2026 | 4.577M |
| September 15, 2026 | 4.203M |
| September 14, 2026 | 4.514M |
| September 11, 2026 | 5.637M |
| September 10, 2026 | 6.323M |
| September 09, 2026 | 7.383M |
| September 08, 2026 | 9.005M |
| September 04, 2026 | 11.81M |
| Date | Value |
|---|---|
| September 03, 2026 | 11.87M |
| September 02, 2026 | 11.81M |
| September 01, 2026 | 11.06M |
| August 31, 2026 | 9.629M |
| August 28, 2026 | 16.18M |
| August 27, 2026 | 17.18M |
| August 26, 2026 | 19.92M |
| August 25, 2026 | 19.67M |
| August 24, 2026 | 16.30M |
| August 21, 2026 | 14.68M |
| August 20, 2026 | 13.25M |
| August 19, 2026 | 16.05M |
| August 18, 2026 | 15.24M |
| August 17, 2026 | 14.09M |
| August 14, 2026 | 16.05M |
| August 13, 2026 | 15.30M |
| August 12, 2026 | 16.74M |
| August 11, 2026 | 18.48M |
| August 10, 2026 | 20.79M |
| August 07, 2026 | 7.945M |
| August 06, 2026 | 7.446M |
| August 05, 2026 | 2.643M |
| August 04, 2026 | 2.706M |
| August 03, 2026 | 1.770M |
| July 31, 2026 | -0.5373M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 267.59B |
| Anika Therapeutics, Inc. | 248.88M |
| BioCryst Pharmaceuticals, Inc. | 2.666B |
| Imunon, Inc. | 6.020M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.504M |
| Revenue (Quarterly) | 27.78M |
| Total Expenses (Quarterly) | 29.28M |
| EPS Diluted (Quarterly) | -0.1442 |
| Gross Profit Margin (Quarterly) | 99.08% |
| Profit Margin (Quarterly) | -5.41% |
| Earnings Yield | -137.0% |
| Normalized Earnings Yield | -141.22 |